ITOC 2022 | The use of chemokines in cancer immunotherapy

Florian Märkl, Ludwig-Maximilians-Universität München, Munich, Germany, discusses various approaches to utilizing chemokines to enhance cancer immunotherapy. This includes inhibition of pro-tumorigenic chemokines and increasing the abundance of anti-tumorigenic chemokines. Additionally, the overexpression of chemokine receptors on CAR-T cells may be used to improve CAR-T cell infiltration into the tumor site. These strategies utilizing and targeting chemokines are being explored for the development of novel drugs. Anti-tumorigenic chemokines in combination with oncolytic viruses and cancer vaccines have demonstrated encouraging results. This interview took place at the Immunotherapy of Cancer (ITOC) Conference 2022 in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.